Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > First time they are in writing discussing acelrsted approval

<< Previous

Bullboard Posts

Next >>

Post by canadafanon Oct 04, 2024 7:59am

250 Views

Post# 36252866

First time they are in writing discussing acelrsted approval

The NR today. Actual an update & ckarigpficationl for the first time very clearly discussing accelerated approval.
To my novice understanding of 5hat ter,pm, obviously good news.
what what does it mean in deatai?

<< Previous

Bullboard Posts

Next >>

Invest wiser with BMO's InvestorLine Platform features